JP2023517312A5 - - Google Patents

Info

Publication number
JP2023517312A5
JP2023517312A5 JP2022553214A JP2022553214A JP2023517312A5 JP 2023517312 A5 JP2023517312 A5 JP 2023517312A5 JP 2022553214 A JP2022553214 A JP 2022553214A JP 2022553214 A JP2022553214 A JP 2022553214A JP 2023517312 A5 JP2023517312 A5 JP 2023517312A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
pharmaceutically acceptable
composition according
humans
hiv infection
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022553214A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023517312A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2021/051765 external-priority patent/WO2021176367A1/en
Publication of JP2023517312A publication Critical patent/JP2023517312A/ja
Publication of JP2023517312A5 publication Critical patent/JP2023517312A5/ja
Pending legal-status Critical Current

Links

JP2022553214A 2020-03-06 2021-03-03 ヒト免疫不全ウイルスの複製阻害剤 Pending JP2023517312A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062985946P 2020-03-06 2020-03-06
US62/985,946 2020-03-06
PCT/IB2021/051765 WO2021176367A1 (en) 2020-03-06 2021-03-03 Inhibitors of human immunodeficiency virus replication

Publications (2)

Publication Number Publication Date
JP2023517312A JP2023517312A (ja) 2023-04-25
JP2023517312A5 true JP2023517312A5 (enExample) 2024-03-13

Family

ID=74870854

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022553214A Pending JP2023517312A (ja) 2020-03-06 2021-03-03 ヒト免疫不全ウイルスの複製阻害剤

Country Status (4)

Country Link
US (1) US20230106880A1 (enExample)
EP (1) EP4114527A1 (enExample)
JP (1) JP2023517312A (enExample)
WO (1) WO2021176367A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11541055B2 (en) 2018-10-24 2023-01-03 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
TW202128648A (zh) * 2019-10-04 2021-08-01 英商Ｖｉｉｖ醫療保健英國(Ｎｏ 5)有限公司 人類免疫不全病毒複製之抑制劑
US20250042926A1 (en) 2023-05-31 2025-02-06 Gilead Sciences, Inc. Therapeutic compounds for hiv
CN121335877A (zh) 2023-06-15 2026-01-13 Viiv保健英国第五有限公司 用于制备化合物的方法和中间体
TW202547514A (zh) 2024-02-05 2025-12-16 英商Ｖｉｉｖ醫療保健英國(Ｎｏ 5)有限公司 人類免疫不全病毒複製之抑制劑

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102464654B (zh) 2010-11-12 2016-01-13 上海泓博智源医药技术有限公司 抗病毒化合物
AU2012278976B2 (en) 2011-07-06 2017-05-11 Gilead Sciences, Inc. Compounds for the treatment of HIV
CN102863512B (zh) 2011-07-07 2016-04-20 上海泓博智源医药技术有限公司 抗病毒化合物
TW201443037A (zh) 2013-01-09 2014-11-16 Gilead Sciences Inc 治療用化合物
US9220710B2 (en) 2013-01-09 2015-12-29 Gilead Sciences, Inc. Therapeutic compounds
ES2642265T3 (es) 2013-01-09 2017-11-16 Gilead Sciences, Inc. Compuestos terapéuticos para el tratamiento de infecciones virales
TWI694071B (zh) * 2013-03-01 2020-05-21 美商基利科學股份有限公司 治療反轉錄病毒科(Retroviridae)病毒感染之治療性化合物
AU2014340110B2 (en) 2013-10-24 2018-07-12 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
US10202353B2 (en) 2014-02-28 2019-02-12 Gilead Sciences, Inc. Therapeutic compounds
WO2015130966A1 (en) 2014-02-28 2015-09-03 Gilead Sciences, Inc. Antiviral agents
EP3186239B1 (en) 2014-08-29 2018-10-10 Gilead Sciences, Inc. Antiretroviral agents
US9855230B2 (en) 2014-09-09 2018-01-02 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
TWI695003B (zh) * 2014-12-23 2020-06-01 美商基利科學股份有限公司 多環胺甲醯基吡啶酮化合物及其醫藥用途
WO2016172425A1 (en) 2015-04-23 2016-10-27 Viiv Healthcare (No.5) Limited Inhibitors of human immunodeficiency virus replication
US10221129B2 (en) 2015-04-23 2019-03-05 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
CN119462611A (zh) 2016-08-19 2025-02-18 吉利德科学公司 用于预防性或治疗性治疗hiv病毒感染的治疗性化合物
TW201906834A (zh) 2017-05-02 2019-02-16 英商Viiv醫療保健英國(No.5)有限公司 人類免疫不全病毒複製之抑制劑
AR112412A1 (es) 2017-08-17 2019-10-23 Gilead Sciences Inc Formas de sal de colina de un inhibidor de la cápside del vih
TWI687415B (zh) 2017-08-17 2020-03-11 美商基利科學股份有限公司 Hiv蛋白質膜抑制劑之固體形式
JP7083398B2 (ja) 2018-02-15 2022-06-10 ギリアード サイエンシーズ， インコーポレイテッド ピリジン誘導体およびｈｉｖ感染を処置するためのその使用
EP3752496B1 (en) 2018-02-16 2023-07-05 Gilead Sciences, Inc. Methods and intermediates for preparing a therapeutic compound useful in the treatment of retroviridae viral infection
EP3774775B8 (en) 2018-04-11 2023-11-15 VIIV Healthcare UK (No.5) Limited 4-oxo-3,4-dihydroquinazoline compounds as inhibitors of human immunodeficiency virus replication

Similar Documents

Publication Publication Date Title
JP2023517312A5 (enExample)
TWI854164B (zh) 苯并吡唑化合物及其類似物
JP3778516B2 (ja) 新規なアリールプロピオン酸誘導体、その製造方法及び鎮痛薬としてのその用途
FI83312B (fi) Foerfarande foer framstaellning av terapeutiskt aktiva 7-(1-pyrrolidinyl)-1-cyklopropyl-6,8-difluor-1,4 -dihydro-4-oxo-3-kinolinkarboxylsyror och deras salter.
JP4523281B2 (ja) Ｈｉｖインテグラーゼ阻害薬として有用なヒドロキシナフチリジノンカルボキサミド類
JP2023506691A5 (enExample)
CN117715906A (zh) 胰高血糖素样肽-1受体调节剂及其用途
JP2024517765A (ja) インテグリン阻害剤の拡大投与レジメン
CN110461858A (zh) 酰基核苷膦酸酯、其前药及其作为药物的用途
JP2023517043A5 (enExample)
JP2022552156A5 (enExample)
EP3962603A1 (en) Inhibitors of human immunodeficiency virus replication
JP2022551256A5 (enExample)
JP2024528962A (ja) シアノピリジンおよびシアノピリミジンｂｃｌ６分解剤
US20030119848A1 (en) Anti acid-fast bacterial agent containing pyridonecarboxylic acids as active ingredient
IL296902A (en) n-Heteroarylalkyl-2-(heterocyclyl and heterocyclylmethyl)acetamide derivatives as sstr4 agonists
JP2025518533A (ja) インテグリン阻害剤の安定化
CN1183778A (zh) 喹啉羧酸衍生物
JP7836529B2 (ja) 腸内分解性共薬、その調製及び使用
JPH02289568A (ja) （ｓ）‐７‐（３‐アミノ‐１‐ピロリジニル）‐１‐シクロプロピル‐６‐フルオロ‐１，４‐ジヒドロ‐４‐オキソ‐１，８‐ナフチリジン‐３‐カルボン酸
JP2006512364A5 (enExample)
CN111936488B (zh) 用于治疗寄生虫感染的新颖化合物
CN111087409B (zh) 一种喹诺酮类化合物及其制备方法和应用
JP7446424B2 (ja) スルホニル尿素環置換単環式β－ラクタム系抗生物質
JP3718262B2 (ja) ホスフィン酸誘導体、その調製方法およびその使用